治疗后肝硬度测量而非治疗期间变化预测HCV治愈后cACLD患者失代偿
该研究回顾性分析15个欧洲中心2,335例HCV治愈的cACLD患者,中位随访6年,评估Baveno VII定义的LSM显著下降标准对失代偿的预测价值。结果显示治疗后LSM是风险分层关键,而LSM动态变化在治疗后LSM 10-19.9 kPa患者中无显著预后信息。
要点
- 治疗后LSM<10 kPa患者5年累积失代偿发生率仅0.3%,风险极低。
- 治疗后LSM≥20 kPa患者5年累积失代偿发生率达16.6%,风险较高。
- 治疗后LSM 10-19.9 kPa患者5年累积发生率1.7%,有无LSM下降≥20%间无差异(p=0.550)。
核心结论
- 治疗后LSM是HCV治愈后风险分层的关键,应指导临床决策。
- 在治疗后LSM 10-19.9 kPa患者中,LSM动态变化不提供显著预后信息,其考虑在该特定背景下增量价值不足。
研究设计与样本
- 回顾性分析15个欧洲中心接受无干扰素治疗实现HCV治愈的cACLD(LSM≥10 kPa)患者,治疗前和治疗后配对LSM。
- 共纳入2,335例患者,中位随访6年。
主要发现
- 基线中位LSM为16.6 kPa,37.1%患者≥20 kPa;治疗后中位LSM降至10.9 kPa,<10 kPa者1,002例(42.9%),≥20 kPa者465例(19.9%)。
- 中位LSM变化为-5.3(-8.8至-2.4)kPa,对应-33.9(-48.0至-15.9)%。
- 达到临床显著下降者(65.4%)肝失代偿风险显著更低(亚分布风险比0.12,95%CI 0.04-0.35,p<0.001)。
- 风险差异主要由治疗后LSM<10 kPa者5年累积发生率0.3%与≥20 kPa者16.6%驱动;治疗后LSM 10-19.9 kPa者(37.4%)5年累积发生率1.7%,有无LSM下降≥20%间无差异(p=0.550)。
关键数值与推荐
- Baveno VII定义临床显著LSM下降为LSM下降≥20%且最终LSM<20 kPa,或任何下降至<10 kPa。
临床怎么用
- 治疗后LSM应指导HCV治愈后cACLD患者的管理。
- 在治疗后LSM 10-19.9 kPa患者中,LSM动态变化不提供增量预后信息,不支持将其作为预后标准考虑。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND & AIMS: Baveno VII has defined a clinically significant (i.e., prognostically meaningful) decrease in liver stiffness measurement (LSM) in cACLD as a decrease of ≥20% associated with a final LSM <20 kPa or any decrease to <10 kPa. However, these rules have not yet been validated against direct clinical endpoints. METHODS: We retrospectively analysed patients with cACLD (LSM ≥10 kPa) with paired liver stiffness measurement (LSM) before (BL) and after (FU) HCV cure by interferon-free therapies from 15 European centres. The cumulative incidence of hepatic decompensation was compared according to these criteria, considering hepatocellular carcinoma and non-liver-related death as competing risks. RESULTS: A total of 2,335 patients followed for a median of 6 years were analysed. Median BL-LSM was 16.6 kPa with 37.1% having ≥20 kPa. After HCV cure, FU-LSM decreased to a median of 10.9 kPa (<10 kPa: 1,002 [42.9%], ≥20 kPa: 465 [19.9%]) translating into a median LSM change of -5.3 (-8.8 to -2.4) kPa corresponding to -33.9 (-48.0 to -15.9) %. Patients achieving a clinically significant decrease (65.4%) had a significantly lower risk of hepatic decompensation (subdistribution hazard ratio: 0.12, 95% CI 0.04-0.35, p <0.001). However, these risk differences were primarily driven by a negligible risk in patients with FU-LSM <10 kPa (5-year cumulative incidence: 0.3%) compared to a high risk in patients with FU-LSM ≥20 kPa (16.6%). Patients with FU-LSM 10-19.9 kPa (37.4%) also had a low risk of hepatic decompensation (5-year cumulative incidence: 1.7%), and importantly, the risk of hepatic decompensation did not differ between those with/without an LSM decrease of ≥20% (p = 0.550). CONCLUSIONS: FU-LSM is key for risk stratification after HCV cure and should guide clinical decision making. LSM dynamics do not hold significant prognostic information in patients with FU-LSM 10-19.9 kPa, and thus, their consideration is not of sufficient incremental value in the specific context of HCV cure. IMPACT AND IMPLICATIONS: Liver stiffness measurement (LSM) is increasingly applied as a prognostic biomarker and commonly decreases in patients with compensated advanced chronic liver disease achieving HCV cure. Although Baveno VII proposed criteria for a clinically significant decrease, little is known about the prognostic utility of LSM dynamics (changes through antiviral therapy). Interestingly, in those with a post-treatment LSM of 10-19.9 kPa, LSM dynamics did not provide incremental information, arguing against the consideration of LSM dynamics as prognostic criteria. Thus, post-treatment LSM should guide the management of patients with compensated advanced chronic liver disease achieving HCV cure.
引用
- Semmler G, Alonso López S, Pons M, et al. Post-treatment LSM rather than change during treatment predicts decompensation in patients with cACLD after HCV cure. J Hepatol. 2024. PMID: 38521170. doi:10.1016/j.jhep.2024.03.015
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。